Solifenacin for Therapy Resistant Overactive Bladder

Hoebeke, Piet; Pooter, Jan De; Caestecker, Karel De; Raes, Ann; Dehoorne, Joke; Laecke, Erik Van; Walle, Johan Vande

doi:10.1016/j.juro.2009.05.100

Cited by 45 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective study of 138 children treated with solinefacin for 23 months, Hoebeke et al noted an overall response rate of 85% and occurrence of side effects in 6.5% of their population. 32 In a prospective, open-label trial on 72 chilren, Bolduc et al noted improved continence in all of their patients, but because of unmanageable side effects, four of their patients had to withdraw from the study. 33 In an extension of this study, Nadeau et al reported an overall success rate of 94%, with greater benefits being observed with higher doses.…”

Section: Other Antimuscarinic Agentsmentioning

confidence: 99%

Overactive bladder in children

Ramsay¹,

Bolduc²

2017

CUAJ

View full text Add to dashboard Cite

Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children's development. From the patient's perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient. A stepwise approach is favoured to treat this pathology, starting with behavioural therapy, followed by medical management, and eventually more invasive procedures.Antimuscarinic agents are the mainstay of medical treatment for OAB. Oxybutynin is the most commonly used antimuscarinic in the pediatric population. However, some patients have a suboptimal response to antimuscarinics and many experience bothersome side effects, which have been documented with all antimuscarinics to a significantly higher degree than placebo. Although there have been reports about the use of tolterodine, fesoterodine, trospium, propiverine, and solifenacin in children, to date, only oxybutynin has been officially approved for pediatric use by medical authorities in North America. This review will address alternative treatment options for pediatric patients presenting with OAB, from conservative measures to more invasive therapies.

show abstract

Section: Other Antimuscarinic Agentsmentioning

confidence: 99%

Overactive bladder in children

Ramsay¹,

Bolduc²

2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…Up-to-date literature on other antimuscarinics, such as tolterodine, solifenacin, propiverine, and trospium, and on novel therapies for OAB, such as the β-3 agonist mirabegron, might encourage physicians and parents to consider other lines of therapy in children presenting with OAB symptoms. [7][8][9][10][11][12][13][14][15][16][17] As a result, changes could eventually be seen in the patterns of therapy and persistence of OAB drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, it is hard to draw conclusions on persistence rates of tolterodine or solifenacin considering the minimal number of patients having used these drugs during the course of our study. Moreover, it is important to remember that solifenacin was listed on the OPDP formulary for the first time in 2011 and that the initial reports on its use in children were only published in 2009 and 2010, 15,17 which can explain the smaller number of patients in this cohort. 26…”

Section: Discussionmentioning

confidence: 99%

Anticholinergic use in children: Persistence and patterns of therapy

Blais¹,

Bergeron²,

Nadeau³

et al. 2016

CUAJ

View full text Add to dashboard Cite

Introduction: Overactive bladder (OAB) symptoms are complex and generally require long-term therapy. Nevertheless, it has been demonstrated that persistence rates of antimuscarinic drug use are low in adults. Better understanding of the treatment patterns of children treated with antimuscarinics could help to improve drug management. Our objective was to evaluate persistence rates of patients under 20 years of age on antimuscarinic therapy over a four-year period. Methods: Patients having received a first-ever antimuscarinic drug prescription between April 2007 and March 2008 were identified using IMS Brogan's Public and Private Drug Plans database. Canadian drug claims data from Private Drug Plans, Régie de l'Assurance Maladie du Québec, and Ontario Public Drug Plans were analyzed retrospectively. Patients were followed for four years to assess the prescribed drugs, the lines of treatment, and the duration of each treatment. Results: Data were available for 374 patients. The most prescribed drug as a first-line therapy was oxybutynin (87.2%), followed by tolterodine LA (5.9%). Patients refilled their index prescriptions for an average of 429 days. Solifenacin had the highest mean duration of index therapy (765 days). The median number of antimuscarinics prescribed was one. At the end of the followup, 44 patients were still on therapy. Reasons for discontinuation of treatment were not available. Conclusions: Overall discontinuation rate of antimuscarinic therapy in children is comparable to what has been reported in adult patients with OAB. However, children seem to persist on the medication for a longer duration before adherence rates start declining. The low rate of persistence highlights the need to identify the reasons for discontinuation of therapy in children in order to obtain better persistence rates.

show abstract

“…Solifenacina: es un nuevo agente selectivo antimuscarínico aún no aprobado en niños, aunque los estudios han probado su utilidad en niños resistentes a oxibutinina y tolterodina (42,43).…”

Section: Tratamiento Farmacológico Anticolinérgicosunclassified

Evaluación y tratamiento del niño con síntomas del tracto urinario inferior (LUTS)

Guerrero-Tinoco

Cano-Martínez

Vanegas-Ruiz

2018

iatreia

View full text Add to dashboard Cite

RESUMENLa disfunción miccional es un trastorno del llenado o vaciado de la vejiga en niños sin alteraciones neurológicas o anatómicas. Los síntomas del tracto urinario inferior (LUTS, por la sigla en inglés de Lower urinary tract symptoms) son un motivo frecuente de consulta con el pediatra, el nefrólogo o el urólogo pediatra, e incluso con el neurólogo y el psicólogo infantil. Se le considera una enfermedad relativamente benigna lo que en ocasiones genera desinterés entre médicos y familiares y lleva a consultas tardías e interpretación inadecuada de los síntomas. Manifestaciones como urgencia, incontinencia, enuresis, goteo posmiccional, infecciones urinarias, vulvovaginitis recurrente y constipación, en un niño sin enfermedad neurológica, deben hacer pensar al médico en disfunción miccional para enfocar oportunamente el diagnóstico, restablecer la calidad de vida del paciente, evitar las infecciones urinarias y el daño renal subsecuente e irreversible secundario a un diagnóstico tardío. Las recomendaciones actuales hacen énfasis en un enfoque menos invasivo, tratamiento conservador, manejo de la constipación y reentrenamiento vesical. Este artículo discute la evaluación, el diagnóstico y el tratamiento correctos de niños con LUTS.

show abstract

Solifenacin for Therapy Resistant Overactive Bladder

Abstract: In this group of children with OAB we noted favorable results with solifenacin with few side effects. Despite the uncontrolled, retrospective study design the effect is attributable to solifenacin intake.

Cited by 45 publications

References 5 publications

Overactive bladder in children

Overactive bladder in children

Anticholinergic use in children: Persistence and patterns of therapy

Evaluación y tratamiento del niño con síntomas del tracto urinario inferior (LUTS)

Contact Info

Product

Resources

About